KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBITDA (2016 - 2025)

Jazz Pharmaceuticals has reported EBITDA over the past 16 years, most recently at $254.5 million for Q4 2025.

  • Quarterly results put EBITDA at $254.5 million for Q4 2025, up 33.43% from a year ago — trailing twelve months through Dec 2025 was -$304.8 million (down 151.18% YoY), and the annual figure for FY2025 was -$430.2 million, down 160.04%.
  • EBITDA for Q4 2025 was $254.5 million at Jazz Pharmaceuticals, up from $57.5 million in the prior quarter.
  • Over the last five years, EBITDA for JAZZ hit a ceiling of $260.2 million in Q3 2024 and a floor of -$686.4 million in Q2 2025.
  • Median EBITDA over the past 5 years was $86.5 million (2022), compared with a mean of $48.7 million.
  • Biggest five-year swings in EBITDA: crashed 633.39% in 2022 and later soared 596.17% in 2023.
  • Jazz Pharmaceuticals' EBITDA stood at $49.4 million in 2021, then crashed by 633.39% to -$263.4 million in 2022, then soared by 146.51% to $122.5 million in 2023, then skyrocketed by 55.73% to $190.8 million in 2024, then surged by 33.43% to $254.5 million in 2025.
  • The last three reported values for EBITDA were $254.5 million (Q4 2025), $57.5 million (Q3 2025), and -$686.4 million (Q2 2025) per Business Quant data.